Recent Articles

FDA Approves Niraparib as Maintenance Therapy for Recurrent Ovarian Cancer

| April 12, 2017 | 0 Comments

FDA Approves Niraparib as Maintenance Therapy for Recurrent Ovarian Cancer The FDA approved the PARP inhibitor niraparib for use as a maintenance therapy for some women with advanced ovarian cancer. See Original Article National Minority Health Month 2017 In recognition of National Minority Health Month, learn more about NCI programs, funding mechanisms, tools, and events […]

Continue Reading

3-D View of Mutations May Identify Potential Targets for Cancer Drugs

| April 11, 2017 | 0 Comments

3-D View of Mutations May Identify Potential Targets for Cancer Drugs A new 3-D modeling tool may help identify mutations in cancer cells that could be targeted with new or existing drugs, a new study suggests. See Original Article Nutritional Requirements of Pancreatic Cancers – A Conversation with Dafna Bar-Sagi Solid tumors in humans develop […]

Continue Reading

Precision Medicine Trials for Cancer: A New Era

| April 11, 2017 | 0 Comments

Precision Medicine Trials for Cancer: A New Era NCI is designing smaller, quicker, and smarter clinical trials that incorporate the principal tenets of precision medicine.See Original Article Program Spotlight: Partnership for the Advancement of Cancer Research Project Brings Cancer Research Training to Underrepresented Students at New Mexico State University The NMSU and FHCRC PACHE partnership […]

Continue Reading

Program Spotlight: Dana Farber/Harvard Cancer Center Partnership Receives $8 Million Grant to Start Center for Personalized Cancer Therapy

| April 10, 2017 | 0 Comments

Program Spotlight: Dana Farber/Harvard Cancer Center Partnership Receives $8 Million Grant to Start Center for Personalized Cancer Therapy The UMass Boston and Dana Farber/Harvard Cancer Center PACHE Partnership received a grant to start-up a Center for Personalized Cancer Therapy on the UMass Boston campus. The center is deigned to train underrepresented students to work in […]

Continue Reading

FDA Approves Ribociclib, Expands Palbociclib Approval for Metastatic Breast Cancer

| April 10, 2017 | 0 Comments

FDA Approves Ribociclib, Expands Palbociclib Approval for Metastatic Breast Cancer The FDA has approved a new targeted therapy, ribociclib, and expanded its earlier approval of another targeted therapy, palbociclib, for some women with metastatic breast cancer. See Original Article FDA Approves Rucaparib for BRCA-Positive Ovarian Cancer The FDA has approved rucaparib for women with BRCA-positive […]

Continue Reading

Common Myths about Cancer and Cancer Health Disparities

| April 10, 2017 | 0 Comments

Common Myths about Cancer and Cancer Health Disparities To better understand cancer and cancer health disparities, CRCHD addresses five common misconceptions about cancer. See Original Article Special Spotlight: Levi A. Garraway, M.D., Ph.D., Receives Prestigious Jane Cooke Wright Award from American Association for Cancer Research Dr. Levi A. Garraway, a former CRCHD CURE trainee, received […]

Continue Reading

Mutation-Specific Approaches to KRAS Cancers: What We Can Learn from G12C-Directed Inhibitors

| April 10, 2017 | 0 Comments

Mutation-Specific Approaches to KRAS Cancers: What We Can Learn from G12C-Directed Inhibitors Dr. Sharon Campbell discusses recent advances in targeting specific mutant forms of KRAS proteins in cancers.See Original Article CURE Scholar Spotlight – Dr. Donita Colette Brady Donita C. Brady, a Research Associate Senior at the Department of Pharmacology and Cancer Biology at Duke […]

Continue Reading

FDA Approves Talimogene Laherparepvec to Treat Metastatic Melanoma

| April 10, 2017 | 0 Comments

FDA Approves Talimogene Laherparepvec to Treat Metastatic Melanoma The FDA has approved the first oncolytic virus therapy, talimogene laherparepvec (T-VEC). The drug was approved for the treatment of metastatic melanoma that cannot be removed surgically.See Original Article TCGA Wins 2015 Sammies People’s Choice Award The Partnership for Public Service presented the 2015 People’s Choice Award […]

Continue Reading

Trial Yields Positive Data on Pembrolizumab for Lung Cancer, Potential Response Biomarker

| April 9, 2017 | 0 Comments

Trial Yields Positive Data on Pembrolizumab for Lung Cancer, Potential Response Biomarker Findings from an early phase clinical trial may point to a biomarker that identifies patients with advanced non-small cell lung cancer most likely to respond to the immunotherapy drug pembrolizumab (Keytruda®). See Original Article Microscopy Advances Open Up New Avenues of Cancer Discovery […]

Continue Reading

Three New Therapies Approved for Multiple Myeloma

| April 9, 2017 | 0 Comments

Three New Therapies Approved for Multiple Myeloma In November 2015, the FDA approved three new therapies for patients with multiple myeloma.See Original Article Long-Term Study Finds No Increased Risk of Miscarriage after HPV Vaccination Women in a clinical trial who became pregnant after vaccination with a bivalent human papillomavirus (HPV) vaccine did not have an […]

Continue Reading